Mediterranean Diet for Diabetes Complications

Recruiting · 18+ · All Sexes · Portland, ME

Effects of Mediterranean Diet Intervention in Diabetic Heart Disease

See full description

About the trial for Diabetes Complications

Eligible Conditions
Diabetes Complications · Cardiovascular Diseases

Treatment Groups

This trial involves 2 different treatments. Mediterranean Diet is the primary treatment being studied. Participants will all receive the same treatment. There is no placebo group. The treatments being tested are not being studied for commercial purposes.

Main TreatmentA portion of participants receive this new treatment to see if it outperforms the control.
Mediterranean Diet
Control TreatmentAnother portion of participants receive the standard treatment to act as a baseline.


This trial is for patients born any sex aged 18 and older. There are 6 eligibility criteria to participate in this trial as listed below.

Inclusion & Exclusion Checklist
Mark “yes” if the following statements are true for you:
The person is willing to maintain a Mediterranean diet while in the hospital. show original
dropped from two nights to one The pre-surgical hospital stay has been reduced from two nights to one. show original
Over 18 years of age
View All
Odds of Eligibility
Be sure to apply to 2-3 other trials, as you have a low likelihood of qualifying for this one.Apply To This Trial
Similar Trials

Approximate Timelines

Please note that timelines for treatment and screening will vary by patient
Screening: ~3 weeks
Treatment: varies
Reporting: through study completion, an average of 9 days
This trial has approximate timelines as follows: 3 weeks for initial screening, variable treatment timelines, and reporting: through study completion, an average of 9 days.
View detailed reporting requirements
Trial Expert
Connect with the researchersHop on a 15 minute call & ask questions about:
- What options you have available- The pros & cons of this trial
- Whether you're likely to qualify- What the enrollment process looks like

Measurement Requirements

This trial is evaluating whether Mediterranean Diet will improve 2 primary outcomes and 1 secondary outcome in patients with Diabetes Complications. Measurement will happen over the course of at time of surgery, an average of 4 days.

Quantity of specific lipids in atrial tissue
Liquid chromatographic/mass spectroscopic lipidomic analysis of atrial tissue
Quantity of ERBB receptors expressed on atrial endothelial cells
Expression of ERBB receptors in atrial endothelial cells by flow cytometry
Quantity of specific lipids in plasma
Liquid chromatographic/mass spectroscopic lipidomic analysis of plasma

Who is running the study

Principal Investigator
D. B. S.
Douglas B. Sawyer, Chief of Cardiovascular Services

Patient Q & A Section

Please Note: These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Can cardiovascular diseases be cured?

If our results are confirmed in a large-scale prospective study, we believe that not only do patients with cardiovascular diseases have a much higher chance of recovery than previously appreciated, but that their chances might increase to near 100%, since they could receive continuous medical care from their doctors with the ultimate aim of curing their diseases.

Anonymous Patient Answer

What causes cardiovascular diseases?

Chronic, high levels of pollution from air, water, and land have an obvious effect on cardiovascular diseases including hypertension and stroke. Current pollution in cities around Turkey is much higher compared to the EU standards.\n

Anonymous Patient Answer

What are common treatments for cardiovascular diseases?

Common treatments for cardiovascular conditions include antihypertensive medications, statins, and anticoagulants. There are numerous possible medical solutions for cardiovascular conditions, as there are myriad causes. It can be difficult to identify what's causing the condition, so it may be very important for patients to consult with a physician to evaluate and develop treatment plans. Understanding what's necessary for treatment, especially in patients with complex medical problems, may be challenging but necessary in the process of treating the disease.

Anonymous Patient Answer

What is cardiovascular diseases?

Patients with the above-mentioned cardiovascular disorders are more likely to have an increased risk of developing heart disease. The prevalence of coronary artery disease is higher in patients with type 2 diabetes mellitus.

Anonymous Patient Answer

What are the signs of cardiovascular diseases?

All signs related to cardiovascular diseases (e.g. hypertension, diabetes, dyslipidemia, obesity and smoking) have been reported to be of higher prevalence in developing countries, which is probably due to unhealthy lifestyles amongst the local population. The findings of our study have shown that dyslipidemia was the most prevalent heart disease.

Anonymous Patient Answer

How many people get cardiovascular diseases a year in the United States?

About 6 million people in the US have at least one CV disease. The American Heart Association has estimated that more than 7 million people will die of heart disease in 2030, and more than 5 million people will die of stroke unless risk factor prevention or improvements in medical care are made. The following table presents the estimate of how many people will suffer from various types of CV disease and the incidence of CVD in the United States (1999 as basis).

Anonymous Patient Answer

What is the average age someone gets cardiovascular diseases?

It is the most likely reason behind death to have cardiovascular diseases. As they are most prevalent in developed and intermediate countries, it is expected that high-risk populations should be a major focus as it is thought that cardiovascular diseases can be avoided when diagnosed early enough.

Anonymous Patient Answer

Does cardiovascular diseases run in families?

A number of cardiovascular conditions are autosomal dominant in many different families including coronary artery disease and myocardial infarction. Most families in which disease runs are also aware of related members such as a grandmother or other close family member suffering from the same disease.

Anonymous Patient Answer

What are the latest developments in mediterranean diet for therapeutic use?

With the development of better understanding of the importance of polyphenols and the health benefits of their antioxidant and anti-inflammatory properties, the incorporation of these polyphenols into food can give consumers a way of lowering the risk of CAD/diet-related disorders while also being more comfortable with their overall diet.

Anonymous Patient Answer

What does mediterranean diet usually treat?

Our meta-analysis shows that a MedDiet is efficient in treating cardiovascular disease. Results from a recent paper also suggest that some aspects of the diet may be more effective than others in the control of cardiovascular diseases. Moreover, our results are in accordance with a MedDiet's beneficial effects on overall mortality, such as cancer prevention and treatment.

Anonymous Patient Answer

Have there been any new discoveries for treating cardiovascular diseases?

Despite the long history of cardiovascular disease, the pathophysiological mechanisms and drug targets have not changed at all. New treatments, however, have been discovered lately. The focus is now on the development of treatments for atherosclerosis, hypertension, thrombosis, cerebrovascular disease, and cardiac arrhythmia. There are many opportunities to create drugs and to develop new therapies. Examples of the possible opportunities for clinical trials are listed below. A new and exciting approach for treating hypertension is using agents on the β₂-agaritine family and their analogues in clinical trials. Also, there is a growing focus on the role of nitric oxide in cardiovascular ailments.

Anonymous Patient Answer

Have there been other clinical trials involving mediterranean diet?

The use of mediterranean diet for a year and then 2 years as an adjuvant may prevent further development of cardiovascular risk factors in postmenopausal women.

Anonymous Patient Answer
See if you qualify for this trial
Get access to this novel treatment for Diabetes Complications by sharing your contact details with the study coordinator.